pc3 cells  (ATCC)

Journal: Oncology Reports

Article Title: Sphingosine-1-phosphate receptor 1 enhances olfactory receptor 51E1-mediated inhibition of proliferation via Src/JNK signaling in prostate cancer cells

doi: 10.3892/or.2026.9103

Figure Lengend Snippet: OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, DU145, and PC3 prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.

Article Snippet: LNCaP cells were obtained from the Korean Cell Line Bank, and Du145 and PC3 cells were purchased from the American Type Culture Collection.

Techniques: Expressing, Cell Counting, Control, Knock-Out, Reverse Transcription, Real-time Polymerase Chain Reaction, Agarose Gel Electrophoresis, Cell Culture, RNA Sequencing, Olfactory

Journal: Signal Transduction and Targeted Therapy

Article Title: Drugging the intrinsically disordered transactivation domain of androgen receptor

doi: 10.1038/s41392-026-02642-3

Figure Lengend Snippet: Improving the potency of compounds. a Structures of compounds ( 1–10 ). b CLogPs and IC 50 s for blocking androgen-induced PSA-luciferase activities in LNCaP cells for compounds ( 1–8 ). c Dose response curves of inhibition of androgen-induced PSA-luciferase activity. d Chemical structures showing the route to BU130/BU170. e , f IC 50 s for pairs of compounds which differed only by the presence (right, red) or absence (left, blue) of the chlorohydrin group using the PSA-luciferase reporter in androgen-induced LNCaP cells. g Table showing the IC 50 s derived from the colony formation assays in LNCaP cells or ( h ) PC3 cells. i Dose response curves from the colony formation assay using LNCaP (solid lines) or PC3 (dashed lines) cells. Blue lines: compounds lacking the chlorohydrin functional group. Red lines: matched compounds with the chlorohydrin. n.s.: not significant. ND: not detected. N/A: not available. Error bars: mean ± SEM. See Supplementary Fig.

Article Snippet: LNCaP cells were obtained from Dr. Lelund Chung (Cedars Sinai Medical Center, Los Angeles, CA), LNCaP95 cells from Dr. Jun Luo (Johns Hopkins University, Baltimore, MD) and PC3 and VCaP cells were obtained from American Type Culture Collection (Manassas, VA).

Techniques: Blocking Assay, Luciferase, Inhibition, Activity Assay, Derivative Assay, Colony Assay, Functional Assay